Quantbot Technologies LP Sells 83,741 Shares of Evolent Health, Inc $EVH

Key Points

• Quantbot Technologies LP reduced its stake in Evolent Health, Inc by 69.8%, selling 83,741 shares and holding 36,315 shares valued at approximately $344,000.
• Multiple institutional investors adjusted their positions in Evolent Health, with US Bancorp DE increasing its stake by 291.0% and Signaturefd LLC raising theirs by 400.6% in the first quarter.
• Wall Street analysts have a consensus rating of "Buy" for Evolent Health, with price targets ranging from $13.00 to $17.93.

Quantbot Technologies LP trimmed its stake in Evolent Health, Inc (NYSE:EVH - Free Report) by 69.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 36,315 shares of the technology company's stock after selling 83,741 shares during the period. Quantbot Technologies LP's holdings in Evolent Health were worth $344,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Banque Cantonale Vaudoise bought a new position in shares of Evolent Health in the 1st quarter valued at approximately $25,000. Rhumbline Advisers raised its stake in shares of Evolent Health by 2.1% in the 1st quarter. Rhumbline Advisers now owns 169,918 shares of the technology company's stock valued at $1,609,000 after acquiring an additional 3,527 shares in the last quarter. US Bancorp DE increased its position in Evolent Health by 291.0% in the 1st quarter. US Bancorp DE now owns 5,153 shares of the technology company's stock worth $49,000 after buying an additional 3,835 shares during the period. MetLife Investment Management LLC increased its position in Evolent Health by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 70,915 shares of the technology company's stock worth $798,000 after buying an additional 4,185 shares during the period. Finally, Signaturefd LLC increased its position in Evolent Health by 400.6% in the 1st quarter. Signaturefd LLC now owns 7,043 shares of the technology company's stock worth $67,000 after buying an additional 5,636 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have commented on EVH shares. JMP Securities reaffirmed a "market outperform" rating and issued a $13.00 price target on shares of Evolent Health in a research report on Friday, June 20th. UBS Group lifted their price target on Evolent Health from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 price target on shares of Evolent Health in a research report on Tuesday, May 13th. Finally, Truist Financial lifted their price target on Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $17.93.

Evolent Health Stock Performance

EVH opened at $9.26 on Wednesday. The stock has a market cap of $1.09 billion, a PE ratio of -5.75 and a beta of 0.82. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. Evolent Health, Inc has a 1 year low of $7.06 and a 1 year high of $32.35. The stock's 50 day simple moving average is $10.11 and its 200-day simple moving average is $9.55.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). The firm had revenue of $444.33 million for the quarter, compared to the consensus estimate of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The business's revenue for the quarter was down 31.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. Sell-side analysts forecast that Evolent Health, Inc will post 0.08 EPS for the current year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.